{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:37:46Z","timestamp":1793731066907,"version":"4.6.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeutic applications of psychedelics may result in a record number of people who use psychedelics for the first-time. This study aimed to develop a harm-reduction resource to facilitate safe and successful psychedelic experiences outside of regulated clinical and research settings. We employed a community-based approach to crowdsource practical recommendations for first-time psychedelic experiences from the psychedelic community.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted an online survey with 581 individuals who reported psychedelic use (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009581) on recommendations for people using psychedelics for the first-time, following the principles of community-based collaborative research. The survey assessed recommendations for and against specific psychedelics for first-time experiences, recommendations for and against combinations of psychedelics, and other advice for first-time experiences. Open-ended follow-up questions were included to understand participants' reasons for their recommendations. An experienced qualitative researcher and two qualitative coders analyzed responses to open-ended items.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most participants recommended psilocybin for first-time psychedelic experiences, approximately half recommended cannabis, and a third recommended MDMA\/MDA (3,4-methylenedioxymethamphetamine\/3,4-methylenedioxyamphetamine, ecstasy, molly). These substances were favored for their moderate intensity, dose-dependent effects, precise dosing, and relatively short duration of effects. Conversely, substances such as ayahuasca, DMT (\n                      <jats:italic>N<\/jats:italic>\n                      ,\n                      <jats:italic>N<\/jats:italic>\n                      -dimethyltryptamine), 5-MeO-DMT (5-methoxy-\n                      <jats:italic>N<\/jats:italic>\n                      ,\n                      <jats:italic>N<\/jats:italic>\n                      -dimethyltryptamine), and\n                      <jats:italic>Salvia divinorum<\/jats:italic>\n                      or salvinorin A were not recommended due to their intensity, mental and physical health risks, and safety concerns. Participants advised against mixing psychedelics with alcohol, stimulants, antidepressants, and narcotics\/opiates. Additional recommendations included embracing the experience, learning about the substance and its effects, and setting intentions for the experience.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Given the growing interest in psychedelics despite limited legal access and systematic education available, it is crucial to inform the public about practices that minimize risks. This project compiled recommendations from individuals who self-identified being experienced with psychedelics. The active involvement of the psychedelic community may enhance research quality and public trust in the findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-025-01337-2","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:10:40Z","timestamp":1764076240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community"],"prefix":"10.1186","volume":"22","author":[{"given":"Daniel J.","family":"Kruger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Mersereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Barron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moss","family":"Herberholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Pouyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob S.","family":"Aday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin F.","family":"Boehnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"2","key":"1337_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478.","journal-title":"Pharmacol Rev"},{"key":"1337_CR2","volume-title":"Storming heaven: LSD and the American dream","author":"J Stevens","year":"1987","unstructured":"Stevens J. Storming heaven: LSD and the American dream. New York: The Atlantic Monthly Press; 1987."},{"key":"1337_CR3","volume-title":"Psychedelic drugs reconsidered","author":"L Grinspoon","year":"1979","unstructured":"Grinspoon L, Bakalar JB. Psychedelic drugs reconsidered. New York: Basic Books; 1979."},{"issue":"3","key":"1337_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/02698811211069100","volume":"36","author":"AK Schlag","year":"2022","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol. 2022;36(3):258\u201372. https:\/\/doi.org\/10.1177\/02698811211069100.","journal-title":"J Psychopharmacol"},{"issue":"9","key":"1337_CR5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1056\/NEJMoa2206443","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330(9):843\u201353. https:\/\/doi.org\/10.1056\/NEJMoa2206443.","journal-title":"JAMA"},{"key":"1337_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02565-4","author":"JM Mitchell","year":"2023","unstructured":"Mitchell JM, Ot\u2019alora GM, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023. https:\/\/doi.org\/10.1038\/s41591-023-02565-4.","journal-title":"Nat Med"},{"key":"1337_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1089\/psymed.2023.0013","volume":"1","author":"JS Aday","year":"2023","unstructured":"Aday JS, Barnett BS, Grossman D, et al. Psychedelic commercialization: a wide-spanning overview of the emerging psychedelic industry. Psychedelic Med. 2023;1:150\u201365. https:\/\/doi.org\/10.1089\/psymed.2023.0013.","journal-title":"Psychedelic Med"},{"key":"1337_CR8","unstructured":"U.S. National Center for Biotechnology Information. U.S. National Library of Medicine; 2024, Available from: https:\/\/www.clinicaltrials.gov\/ [Last accessed: 12\/12\/2024]"},{"key":"1337_CR9","volume-title":"How to change your mind","author":"M Pollan","year":"2018","unstructured":"Pollan M. How to change your mind. New York: Penguin Books; 2018."},{"issue":"3","key":"1337_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1080\/02791072.2019.1581961","volume":"51","author":"JS Aday","year":"2019","unstructured":"Aday JS, Bloesch EK, Davoli CC. Beyond LSD: a broader psychedelic zeitgeist during the early to mid-20th century. J Psychoactive Drugs. 2019;51(3):210\u20137. https:\/\/doi.org\/10.1080\/02791072.2019.1581961.","journal-title":"J Psychoactive Drugs"},{"key":"1337_CR11","unstructured":"Psychedelic Alpha. Psychedelics legalization & decriminalization tracker. 2024. https:\/\/psychedelicalpha.com\/data\/psychedelic-laws. Last accessed: 12 Dec 2024"},{"issue":"1","key":"1337_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1556\/2054.2020.00159","volume":"5","author":"RA Yockey","year":"2021","unstructured":"Yockey RA, King K. Use of psilocybin (\u201cmushrooms\u201d) among US adults: 2015\u20132018. J Psychedelics Stud. 2021;5(1):17\u201321. https:\/\/doi.org\/10.1556\/2054.2020.00159.","journal-title":"J Psychedelics Stud"},{"key":"1337_CR13","doi-asserted-by":"publisher","first-page":"108071","DOI":"10.1016\/j.drugalcdep.2020.108071","volume":"212","author":"RA Yockey","year":"2020","unstructured":"Yockey RA, Vidourek RA, King KA. Trends in LSD use among US adults: 2015\u20132018. Drug Alcohol Depend. 2020;212:108071. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108071.","journal-title":"Drug Alcohol Depend"},{"key":"1337_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00489-1","volume":"18","author":"B Pilecki","year":"2021","unstructured":"Pilecki B, Luoma JB, Bathje GJ, et al. Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduct J. 2021;18:40. https:\/\/doi.org\/10.1186\/s12954-021-00489-1.","journal-title":"Harm Reduct J"},{"key":"1337_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12954-022-00662-0","volume":"19","author":"M Palmer","year":"2022","unstructured":"Palmer M, Maynard OM. Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience. Harm Reduct J. 2022;19:81. https:\/\/doi.org\/10.1186\/s12954-022-00662-0.","journal-title":"Harm Reduct J"},{"key":"1337_CR16","unstructured":"Gallivan, J. Advocates and providers aim to lower cost of psilocybin treatment. Axios Portland. Jun 26, 2024. https:\/\/www.axios.com\/local\/portland\/2024\/06\/26\/psilocybin-services-magic-mushroom-treatment-price-oregon"},{"issue":"16","key":"1337_CR17","doi-asserted-by":"publisher","first-page":"7619","DOI":"10.1017\/S0033291723001411","volume":"53","author":"P McCrone","year":"2023","unstructured":"McCrone P, Fisher H, Knight C, et al. Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model. Psychol Med. 2023;53(16):7619\u201326. https:\/\/doi.org\/10.1017\/S0033291723001411.","journal-title":"Psychol Med"},{"issue":"5","key":"1337_CR18","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1073\/pnas.1918477117","volume":"117","author":"M Forstmann","year":"2020","unstructured":"Forstmann M, Yudkin DA, Prosser AMB, Heller SM, Crockett MJ. Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings. Proc Natl Acad Sci U S A. 2020;117(5):2338\u201346. https:\/\/doi.org\/10.1073\/pnas.1918477117.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1337_CR19","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","volume":"376","author":"DJ Nutt","year":"2010","unstructured":"Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376:1558\u201365.","journal-title":"Lancet"},{"issue":"12","key":"1337_CR20","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","volume":"81","author":"JT Hinkle","year":"2024","unstructured":"Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse events in studies of classic psychedelics: a systematic review and meta-analysis. JAMA Psychiatr. 2024;81(12):1225\u201335. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.2546.","journal-title":"JAMA Psychiatr"},{"issue":"5","key":"1337_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","volume":"80","author":"S McNamee","year":"2023","unstructured":"McNamee S, Devenot N, Buisson M. Studying harms is key to improving psychedelic-assisted therapy\u2014participants call for changes to research landscape. JAMA Psychiatr. 2023;80(5):411\u20132. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.0099.","journal-title":"JAMA Psychiatr"},{"key":"1337_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/02791072.1998.10399712","volume":"30","author":"JC Callaway","year":"1998","unstructured":"Callaway JC, Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J Psychoact Drugs. 1998;30:367\u20139. https:\/\/doi.org\/10.1080\/02791072.1998.10399712.","journal-title":"J Psychoact Drugs"},{"key":"1337_CR23","unstructured":"Mustafa RA, McQueen B, Nikitin D, Nhan E, Zemplenyi A, DiStefano MJ, Kayali Y, Richardson M, Rind DM. MDMA-assisted psychotherapy for post-traumatic stress disorder: effectiveness and value; evidence report. Institute for Clinical and Economic Review, May 14, 2024. https:\/\/icer.org\/assessment\/ptsd-2024\/#overview"},{"issue":"6","key":"1337_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamapsychiatry.2023.0549","volume":"80","author":"JS Aday","year":"2023","unstructured":"Aday JS, Carhart-Harris RL, Woolley JD. Emerging challenges for psychedelic therapy. JAMA Psychiatr. 2023;80(6):533\u20134. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.0549.","journal-title":"JAMA Psychiatr"},{"issue":"11","key":"1337_CR25","doi-asserted-by":"publisher","first-page":"e0000438","DOI":"10.1371\/journal.pgph.0000438","volume":"2","author":"JC Bouso","year":"2022","unstructured":"Bouso JC, Andi\u00f3n \u00d3, Sarris JJ, et al. Adverse effects of ayahuasca: results from the Global Ayahuasca Survey. PLOS Glob Public Health. 2022;2(11):e0000438. https:\/\/doi.org\/10.1371\/journal.pgph.0000438.","journal-title":"PLOS Glob Public Health"},{"key":"1337_CR26","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2024.0011","author":"DJ Kruger","year":"2024","unstructured":"Kruger DJ, Aday JS, Fields C, Kolbman N, Glynos N, Barron J, et al. Psychedelic therapist sexual misconduct and other adverse experiences among a sample of naturalistic psychedelic users. Psychedelic Med. 2024. https:\/\/doi.org\/10.1089\/psymed.2024.0011.","journal-title":"Psychedelic Med"},{"key":"1337_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12954-023-00908-5","volume":"20","author":"Y Milshteyn","year":"2023","unstructured":"Milshteyn Y, Bensimon M. Exploring the subjective experience of rave party participants in Israel who consume psychedelic drugs: a qualitative inquiry. Harm Reduct J. 2023;20:176. https:\/\/doi.org\/10.1186\/s12954-023-00908-5.","journal-title":"Harm Reduct J"},{"issue":"10","key":"1337_CR28","doi-asserted-by":"publisher","first-page":"e0293349","DOI":"10.1371\/journal.pone.0293349","volume":"18","author":"J Evans","year":"2023","unstructured":"Evans J, Robinson OC, Argyri EK, et al. Extended difficulties following the use of psychedelic drugs: a mixed methods study. PLoS ONE. 2023;18(10):e0293349. https:\/\/doi.org\/10.1371\/journal.pone.0293349.","journal-title":"PLoS ONE"},{"issue":"6","key":"1337_CR29","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/0306-4603(96)00042-1","volume":"21","author":"GA Marlatt","year":"1996","unstructured":"Marlatt GA. Harm reduction: come as you are. Addict Behav. 1996;21(6):779\u201388. https:\/\/doi.org\/10.1016\/0306-4603(96)00042-1.","journal-title":"Addict Behav"},{"issue":"2","key":"1337_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.drugpo.2007.01.003","volume":"18","author":"P O'Hare","year":"2007","unstructured":"O\u2019Hare P. Merseyside, the first harm reduction conferences, and the early history of harm reduction. Int J Drug Policy. 2007;18(2):141\u20134. https:\/\/doi.org\/10.1016\/j.drugpo.2007.01.003.","journal-title":"Int J Drug Policy"},{"key":"1337_CR31","doi-asserted-by":"crossref","unstructured":"Riley D,\u00a0O'Hare P. Harm reduction: History, definition, and practice. In: Inciardi, Harrison, editors. Harm reduction: national and international perspectives. Sage; 2000.","DOI":"10.4135\/9781452220680.n1"},{"key":"1337_CR32","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Harm reduction framework. Substance Abuse and Mental Health Services Administration. 2023. https:\/\/www.samhsa.gov\/find-help\/harm-reduction"},{"issue":"1","key":"1337_CR33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/1471-2458-14-297","volume":"14","author":"M Doe-Simkins","year":"2014","unstructured":"Doe-Simkins M, Quinn E, Xuan Z, Sorensen-Alawad A, Hackman H, Ozonoff A, et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health. 2014;14(1):297. https:\/\/doi.org\/10.1186\/1471-2458-14-297.","journal-title":"BMC Public Health"},{"key":"1337_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12954-023-00845-3","volume":"20","author":"H Bonny-Noach","year":"2023","unstructured":"Bonny-Noach H, Shapira B, Baumol P, et al. Substance use, harm reduction attitudes and behaviors among attendees of nature rave parties in Israel. Harm Reduct J. 2023;20:108. https:\/\/doi.org\/10.1186\/s12954-023-00845-3.","journal-title":"Harm Reduct J"},{"issue":"6","key":"1337_CR35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"MW Johnson","year":"2008","unstructured":"Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603\u201320. https:\/\/doi.org\/10.1177\/0269881108093587.","journal-title":"J Psychopharmacol"},{"key":"1337_CR36","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fpsyg.2021.645246","volume":"12","author":"I Gorman","year":"2021","unstructured":"Gorman I, Nielson EM, Molinar A, Cassidy K, Sabbagh J. Psychedelic harm reduction and integration: a transtheoretical model for clinical practice. Front Psychol. 2021;12:710. https:\/\/doi.org\/10.3389\/fpsyg.2021.645246.","journal-title":"Front Psychol"},{"issue":"9","key":"1337_CR37","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/0269881119855974","volume":"33","author":"L Roseman","year":"2019","unstructured":"Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R. Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. J Psychopharmacol. 2019;33(9):1076\u201387. https:\/\/doi.org\/10.1177\/0269881119855974.","journal-title":"J Psychopharmacol"},{"key":"1337_CR38","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2024.0011","author":"DJ Kruger","year":"2024","unstructured":"Kruger DJ, Aday JS, Fields C, Kolbman N, Glynos N, Barron J, et al. Psychedelic therapist sexual misconduct and other adverse experiences among a sample of naturalistic psychedelic users. Psychedelic Med. 2024. https:\/\/doi.org\/10.1089\/psymed.2024.0011.","journal-title":"Psychedelic Med"},{"key":"1337_CR39","unstructured":"Lennon J., McCartney P. Tomorrow never knows. In the Beatles,\u00a0Revolver. London, UK: EMI Records. 1966."},{"key":"1337_CR40","volume-title":"The psychedelic experience: a manual based on the Tibetan book of the dead","author":"T Leary","year":"1964","unstructured":"Leary T, Metzner R, Alpert R. The psychedelic experience: a manual based on the Tibetan book of the dead. New York: University Books; 1964."},{"key":"1337_CR41","volume-title":"The Tibetan book of the dead","author":"WY Evans-Wentz","year":"1927","unstructured":"Evans-Wentz WY, Samdup KD. The Tibetan book of the dead. Oxford: Oxford University Press; 1927."},{"issue":"11","key":"1337_CR42","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.2105\/AJPH.2009.170506","volume":"100","author":"BA Israel","year":"2010","unstructured":"Israel BA, Coombe CM, Cheezum RR, Schulz AJ, McGranaghan RJ, Lichtenstein R, et al. Community-based participatory research: a capacity-building approach for policy advocacy aimed at eliminating health disparities. Am J Public Health. 2010;100(11):2094\u2013102. https:\/\/doi.org\/10.2105\/AJPH.2009.170506.","journal-title":"Am J Public Health"},{"key":"1337_CR43","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1037\/h0032231","volume":"26","author":"JG Kelly","year":"1971","unstructured":"Kelly JG. Qualities for the community psychologist. Am Psychol. 1971;26:897\u2013903. https:\/\/doi.org\/10.1037\/h0032231.","journal-title":"Am Psychol"},{"key":"1337_CR44","first-page":"143","volume-title":"Resolving social conflicts, selected papers on group dynamic","author":"K Lewin","year":"1946","unstructured":"Lewin K. Action research and minority problems. In: Lewin GW, editor. Resolving social conflicts, selected papers on group dynamic. Washington: American Psychological Association; 1946. p. 143\u201352."},{"key":"1337_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF00919275","volume":"15","author":"J Rappaport","year":"1987","unstructured":"Rappaport J. Terms of empowerment\/exemplars of prevention: toward a theory for community psychology. Am J Community Psychol. 1987;15:121\u201348. https:\/\/doi.org\/10.1007\/BF00919275.","journal-title":"Am J Community Psychol"},{"key":"1337_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.addicn.2022.100025","volume":"3","author":"FR Mendes","year":"2022","unstructured":"Mendes FR, dos Santos Costa C, Wiltenburg VD, et al. Classic and non-classic psychedelics for substance use disorder: a review of their historic, past and current research. Addict Neurosci. 2022;3:100025. https:\/\/doi.org\/10.1016\/j.addicn.2022.100025.","journal-title":"Addict Neurosci"},{"key":"1337_CR47","unstructured":"Wittgenstein L. Philosophische Untersuchungen\/ Philosophical investigations. Blackwell Publishers, 1953"},{"issue":"8","key":"1337_CR48","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/02698811241265756","volume":"38","author":"R Palitsky","year":"2024","unstructured":"Palitsky R, Kaplan DM, Perna J, et al. A framework for assessment of adverse events occurring in psychedelic-assisted therapies. J Psychopharmacol. 2024;38(8):690\u2013700. https:\/\/doi.org\/10.1177\/02698811241265756.","journal-title":"J Psychopharmacol"},{"key":"1337_CR49","unstructured":"Kruger DJ, Aday JS, Boehnke KF, Bradley MK, Lake S, Mashour GA, Lucas, P. Which substances are psychedelics? Manuscript submitted for review. 2025."},{"key":"1337_CR50","first-page":"69","volume-title":"Psychedelic medicine: new evidence for hallucinogenic substances as treatments","author":"E Frecska","year":"2007","unstructured":"Frecska E. Therapeutic guidelines: dangers and contra-indications in therapeutic applications of hallucinogens. In: Psychedelic medicine: new evidence for hallucinogenic substances as treatments. Westport: Praeger Publishers; 2007. p. 69\u201395."},{"key":"1337_CR51","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12954-024-01104-9","volume":"21","author":"AB Gomes","year":"2024","unstructured":"Gomes AB, Sultan A. Problematizing content moderation by social media platforms and its impact on digital harm reduction. Harm Reduct J. 2024;21:194. https:\/\/doi.org\/10.1186\/s12954-024-01104-9.","journal-title":"Harm Reduct J"},{"issue":"5","key":"1337_CR52","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/02791072.2023.2201263","volume":"55","author":"DJ Kruger","year":"2023","unstructured":"Kruger DJ, Enghoff O, Herberholz M, Barron J, Boehnke KF. How do I learn more about this?\" Utilization and trust of psychedelic information sources among people naturalistically using psychedelics. J Psychoact Drugs. 2023;55(5):631\u20139. https:\/\/doi.org\/10.1080\/02791072.2023.2201263.","journal-title":"J Psychoact Drugs"},{"key":"1337_CR53","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00213-021-05876-x","volume":"239","author":"B Malcolm","year":"2022","unstructured":"Malcolm B, Thomas K. Serotonin toxicity of serotonergic psychedelics. Psychopharmacology. 2022;239:1881\u201391. https:\/\/doi.org\/10.1007\/s00213-021-05876-x.","journal-title":"Psychopharmacology"},{"key":"1337_CR54","doi-asserted-by":"publisher","DOI":"10.21428\/88de04a1.cb6fef95","author":"CB Dollar","year":"2021","unstructured":"Dollar CB. Recreation and realization: reported motivations of use among persons who consume psychedelics in non-clinical settings. J Qual Crim Justice Criminol. 2021. https:\/\/doi.org\/10.21428\/88de04a1.cb6fef95.","journal-title":"J Qual Crim Justice Criminol"},{"issue":"2","key":"1337_CR55","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/17512433.2023.2295997","volume":"17","author":"LF Borkel","year":"2023","unstructured":"Borkel LF, Rojas-Hern\u00e1ndez J, Henr\u00edquez-Hern\u00e1ndez LA, Santana Del Pino \u00c1, Quintana-Hern\u00e1ndez DJ. Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study. Expert Rev Clin Pharmacol. 2023;17(2):165\u201376. https:\/\/doi.org\/10.1080\/17512433.2023.2295997.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1337_CR56","doi-asserted-by":"publisher","first-page":"102997","DOI":"10.1016\/j.drugpo.2020.102997","volume":"87","author":"L Gashi","year":"2020","unstructured":"Gashi L, Sandberg S, Pedersen W. Making, \u201cbad trips\u201d good: How users of psychedelics narratively transform challenging trips into valuable experiences. Int J Drug Policy. 2020;87:102997. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102997.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1337_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1037\/cns0000169","volume":"6","author":"SL Russ","year":"2019","unstructured":"Russ SL, Carhart-Harris RL, Maruyama G, Elliott MS. States and traits related to the quality and consequences of psychedelic experiences. Psychol Conscious. 2019;6(1):1\u201321. https:\/\/doi.org\/10.1037\/cns0000169.","journal-title":"Psychol Conscious"},{"issue":"3","key":"1337_CR58","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/02698811241232548","volume":"38","author":"A Marrocu","year":"2024","unstructured":"Marrocu A, Kettner H, Weiss B, Zeifman RJ, Erritzoe D, Carhart-Harris RL. Psychiatric risks for worsened mental health after psychedelic use. J Psychopharmacol. 2024;38(3):225\u201335. https:\/\/doi.org\/10.1177\/02698811241232548.","journal-title":"J Psychopharmacol"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01337-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01337-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01337-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:10:47Z","timestamp":1764076247000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01337-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1337"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01337-2","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project (HUM00205639) was reviewed by the University of Michigan Health and Behavioral Sciences Institutional Review Board prior to data collection. Informed consent was obtained from all participants included in the study. Participants were not compensated and could withdraw at any time.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have contributed substantially to the project and have approved the final version of this manuscript to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article. KFB\u2019s effort on this publication was partially supported by the National Institute on Drug Abuse of the National Institutes of Health under K01DA049219. KFB has received grant funding from Tryp Therapeutics for protocol development. JB is the Founder\/President of the Michigan Psychedelic Society and is a Psychedelic Integration and Music Therapist at Blue Sage Health Consulting. JSA\u2019s effort on this publication was partially supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under T32AR007080-44S1.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}